Lila Adnane

发表论文 29 篇 · 总被引 7486 次 · h-index 7

代表论文

• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis (2004 · Cancer Research · 被引 4058)
• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (2008 · Molecular Cancer Therapeutics · 被引 1469)
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (2010 · International Journal of Cancer · 被引 1357)
• Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature (2006 · Methods in enzymology on CD-ROM/Methods in enzymology · 被引 475)
• Therapeutic Mechanism and Efficacy of the Antibody–Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9 (2011 · Molecular Cancer Therapeutics · 被引 68)
• Recent Advances in the Research and Development of RAF Kinase Inhibitors (2006 · Current Topics in Medicinal Chemistry · 被引 48)